RT Journal Article
SR Electronic
T1 CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 935
OP 939
VO 37
IS 2
A1 SONE, KAZUKI
A1 OGURI, TETSUYA
A1 NAKAO, MAKOTO
A1 KAGAWA, YUSUKE
A1 KUROWAKA, RYOTA
A1 FURUTA, HIROMI
A1 FUKUDA, SATOSHI
A1 UEMURA, TAKEHIRO
A1 TAKAKUWA, OSAMU
A1 KANEMITSU, YOSHIHIRO
A1 OHKUBO, HIROTSUGU
A1 TAKEMURA, MASAYA
A1 MAENO, KEN
A1 ITO, YUTAKA
A1 SATO, HIDEFUMI
A1 MURAMATSU, HIDEKI
A1 NIIMI, AKIO
YR 2017
UL http://ar.iiarjournals.org/content/37/2/935.abstract
AB Background: Pretreatment serum tumor marker levels predict outcome in non-small cell lung cancer (NSCLC). However, little is known about the clinical value of such measurements for patients treated with pemetrexed plus a platinum-derivative. Patients and Methods: We retrospectively screened 100 chemotherapy-naïve patients with advanced non-squamous NSCLC treated with pemetrexed plus a platinum-derivative in relation to the pretreatment level of cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA). Results: Sixty one patients with a high CYFRA 21-1 level had statistically shorter progression-free and overall survival than 39 patients with a normal CYFRA 21-1 level (median progression-free survival=127 days vs. 191 days, respectively; p=0.046; median overall survival=360 days vs. 781 days, respectively, p<0.001). Serum CEA level was not related to survival. Conclusion: Serum CYFRA 21-1 level is a predictive and prognostic marker in patients with NSCLC treated with pemetrexed plus a platinum-derivative.